Navigation Links
$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
Date:9/11/2008

WALNUT CREEK, Calif., Sept. 11 /PRNewswire/ -- A project to advance research and improve treatments for fragile X syndrome will be funded by a new $1.6 million, three-year cooperative agreement with the Center for Disease Control (CDC) and others.

The agreement, intended to bring better care to the more than 100,000 affected Americans, is between The National Fragile X Foundation (NFXF), the CDC's National Center on Birth Defects and Developmental Disabilities, the Association of University Centers on Disabilities, the New York State Institute for Basic Research in Developmental Disabilities and the Data Coordinating Center at Columbia University.

Fragile X syndrome is the most common known cause of inherited intellectual disability and the most common known single gene cause of autism.

The effort will advance the core activities of the Fragile X Clinical and Research Consortium (FXCRC). The NFXF initiated the FXCRC in 2006 to advance clinical practice and facilitate coordinated, collaborative multi-site research. The FXCRC has been meeting regularly since its inception to address best practices in evaluation and treatment, including pharmacological, therapeutic and educational treatments, strategies for supporting and enhancing clinic work, and research priorities. The NFXF prioritized its support of a clinics consortium when it realized the body of Fragile X expertise was scattered throughout North America and organizing that expertise would enhance existing and future research efforts while simultaneously making clinical evaluation and treatment more easily accessible to families.

"The fact the consortium has moved from concept to reality to government funding so quickly is a testament to the organization, its leadership and the families that each year travel to Washington, D.C., to urge Congress to support this important cause," said Jeffrey Cohen, chair, NFXF Public Policy Committee, and father of a son and daughter with fragile X syndrome.

The FXCRC will also address other related conditions such as fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency which potentially impact over one million adult male and female carriers in the U.S.


'/>"/>
SOURCE The National Fragile X Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
2. Yongye Biotechnology International Raises $9.4 Million in Private Placement
3. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
6. Proteolix Raises $79 Million in Series C Financing
7. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
8. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
9. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
10. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
11. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
Breaking Biology News(10 mins):